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Abstract 
Smooth muscle cell (SMC)-based tissue engineering provides a promising therapeutic 
strategy for SMC related disorders. It has been demonstrated that human dental pulp 
stem cells (DPSCs) possess the potential to differentiate into mature bladder SMCs by 
induction with condition medium (CM) from bladder SMC culture, in combination with 
the Transforming Growth Factor-β1 (TGF-β1). However, the molecular mechanism of 
SMC differentiation from DPSCs has not been fully uncovered. Canonical Wnt 
signaling (also known as Wnt/β-catenin) pathway plays an essential role in stem cell 
fate decision. The aim of this study is to explore the regulation via GSK3β and 
associated downstream effectors for SMC differentiation from DPSCs. We 
characterized one of our DPSC clones with the best proliferation and differentiation 
abilities. This stem cell clone has shown the capacity to generate a smooth muscle layer-
like phenotype after an extended differentiation duration using the SMCs induction 
protocol we established before. We further found that Wnt-GSK3β/β-catenin signaling 
is involved in the process of SMCs differentiation from DPSCs, as well as a serial of 
growth factors, including TGF-β1, basic fibroblast growth factor (bFGF), epidermal 
growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor-
homodimer polypeptide of B chain (BB) (PDGF-BB), and vascular endothelial growth 
factor (VEGF). Pharmacological inhibition on canonical Wnt-GSK3β/β-catenin 
pathway significantly down-regulated GSK3β phosphorylation and β-catenin activation, 
which in consequence reduced the augmented expression of the growth factors 
(including TGF-β1, HGF, PDGF-BB, and VEGF) as well as SMC markers (especially 
myosin) at a late stage of SMC differentiation. These results suggest that canonical 
Wnt-GSK3β/β-catenin pathway contributes to DPSC differentiation into mature SMCs 
through the coordination of different growth factors.  
 
 
 
Introduction 
A range of injuries or diseases including cancer, benign bladder contracture and 
congenital anomalies (such as bladder exstrophy and myelomeningocele) can result in 
the damage or loss of bladder [1-3]. Consequently patients with those illnesses require 
bladder augmentation cystoplasty or replacement. However, current cystoplasty using 
gastrointestinal segments cannot completely restore the normal function of Detrusor 
muscle, in some cases even leading to complications, such as metabolic disturbances, 
urolithiasis, infection and malignant diseases [4, 5]. Therefore, bladder smooth muscle 
cell-based tissue engineering becomes one of the most promising remedies for restoring 
bladder organ function of the urinary system [6, 7]. However, due to the limited 
expansion of bladder tissue-derived SMCs and highly potential oncogenic risk, the 
progress of bladder tissue engineering is hampered by lack of a stable SMC source [8, 
9]. Thus search for alternative cell source is essential for bladder tissue engineering, 
which could provide a new way to overcome the shortcomings of the aforementioned 
methods in the future.  
Mesenchymal stem cells (MSCs) are one type of fibroblast-like cell population with 
potential extensive self-renewal and multi-lineage differentiation abilities [10]. 
Compared with other MSCs derived from bone marrow [11], adipose tissue [12], 
peripheral blood [13] and umbilical cord blood [14], MSCs derived from dental pulp 
tissues have marked advantages of easy access with the least invasive procedures and 
capacities of high proliferation, excellent regeneration and multiple-potential of 
differentiation along with little inherent immunogenicity, which make them particularly 
suitable for tissue engineering and gene therapy applications [15, 16]. Dental pulp stem 
cells (DPSCs) are normally isolated using a single colony method as DPSCs from pulp 
tissue are heterogeneous, which are expected to produce complex biological activities 
[17, 18]. For this reason, different clones of DPSCs exhibit different behaviours 
including various capacities of proliferation and differentiation according to the age of 
the donor, method of isolation and conditions of the pulp tissue [19]. DPSCs provide a 
potential source of progenitor cells for tissue engineering. However, the abilities of 
expansion and differentiation in vitro should be fully explored before use. In this study, 
we have isolated three DPSC clones from different patients. The clones were 
investigated by comparing their proliferation rates and potential to differentiate into 
three mesenchymal lineages (namely osteogenic, adipogenic and chondrogenic), to 
determine the best clone as the candidate cell source for further tissue engineering 
research.  
We have recently reported the feasibility of using human DPSCs as bladder SMC 
progenitors for the regeneration of SMCs [20]. Although the capacity of DPSCs 
differentiation into SMCs have been demonstrated, whether they can form a smooth 
muscle layer and its underlying molecular mechanisms remains largely unknown. The 
Wnt signaling pathway is an ancient and evolutionarily conserved pathway which 
orchestrates a range of biological processes, such as cell fate determination during 
embryonic development, cell proliferation, cell cycle arrest, differentiation, apoptosis, 
as well as tissue homeostasis [21]. β-catenin is a plasma membrane-associated protein 
that acts as an intracellular signaling transducer in the Wnt signaling pathway [22]. It 
has been demonstrated to induce the myogenic differentiation of rat MSCs through up-
regulation of myogenic regulatory factors [23].Glycogen synthase kinase 3β (GSK3β) 
is a proline-directed serine-threonine kinase and its phosphorylation appears to be a 
critical step in directing β-catenin to the nucleus [22]. Myogenic growth factors, 
including platelet-derived growth factor-homodimer polypeptide of B chain (PDGF-
BB), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor 
(VEGF), as well as hepatocyte growth factor (HGF) have been proven to play a vital 
role in SMC differentiation in vivo [24].Therefore, the aim of this study is to analyse 
the mechanisms of Wnt sigalling pathway and the expression of myogenic growth 
factors involved in the regulation of differentiation of DPSCs toward bladder SMCs 
using the in vitro model we established before.  
 
 
Materials and Methods 
Human DPSCs clones and SMCs isolation 
The pulp tissues were obtained from third molars (donors aged from 17 to 20 years) 
with the patient’s informed consent and ethical approval by the South East Wales 
Research Ethics Committee of the National Research Ethics Service (permission 
number: 07/WESE04/84). The clonal populations of DPSCs were isolated using 
fibronectin based selection protocol as described previously [20, 25] after ethical 
approval and patient consent (permission number: 07/WESE04/84). Following 12 days 
of culture, single cell-derived clones were isolated using cloning rings and accutase 
digestion, and then expanded. Three clones were selected, named as A11, B11 and A32. 
The level of population doublings (PDs) during expansion culture was monitored to 
measure the proliferation rate of three clones [20]. Then three clones were induced to 
differentiate into three mesenchymal lineages (including osteogenic, adipogenic and 
chondrogenic) in appropriate differentiation condition in vitro to compare their 
capacities of differentiation. 
Human SMCs were obtained as reported previously from the bladder of patients who 
underwent open procedures for their bladder, after patient consent and ethical approval 
by the South East Wales Research Ethics Committee of the National Research Ethics 
Service (permission number: 07/WESE04/84) [20]. Briefly, bladder muscle tissue was 
minced into 1 x 1 mm pieces and digested in collagenase type IV enzyme (Sigma- 
Aldrich) for 30 minutes at 37°C. The digested muscle tissues were plated in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% FBS for establishing primary culture. 
Differentiation of human DPSCs clone A32 and Wnt pathway inhibition assay 
Differentiation of the A32 was induced by using conditioned medium (CM) collected 
from bladder SMCs culture, supplemented with transforming growth factor beta 1 
(TGF-β1), as previously described [20].  
The Wnt pathway was analysed by using the inhibitors including XAV939 (Wnt/β-
catenin signaling inhibitor, Sigma), SB216763 (GSK-3 inhibitor, Sigma) and LiCl 
(GSK-3 inhibitor, Sigma), as previously described [26-28]. Briefly, cells were seeded 
into 6-well plate. At 80% confluence of cells, the culturing medium was changed into 
the bladder SMCs differentiation induction medium with the XAV939 (5μM), 
SB216763 (20μM) or LiCl (2.5mM), respectively. Equivalent amount of 
dimethylsulfoxide was added to the control wells. After 14 days of incubation, the 
mRNA and protein levels were compared to the control group using qPCR and western 
blotting methods, respectively. 
Immunocytochemistry 
The cells were fixed with 4 % PFA for 30 min and then incubated in 0.1% Triton X-
100 for 10 min on ice and then blocked with bovine serum albumin (BSA) for 60 min 
at 37 °C. After the blocking step, the cells were incubated with anti-myosin (1:50), anti-
α-SMA (1:100) and anti-desmin (1:50) at 4 °C, overnight; PBS was used as the negative 
control. The cells were then washed with PBS for 3 times and incubated with anti-
mouse IgG Alexa Fluor-488 or -594 secondary antibodies for 1 h at room temperature. 
The nuclei were counterstained with DAPI (VectorLabs). The protein expressions were 
observed with fluorescent microscope, and analysed with ImageJ software. 
Flow cytometry 
The cells were washed and re-suspended in PBS supplemented with 3 % FBS that 
contained saturating concentrations (1:100 dilution) of the following reagents: FITC-
conjugated anti-human monoclonal antibodies, anti-CD29-phycoerythrin (PE), anti-
CD90-PE, anti-CD34-PE, anti-CD45-PE, anti-CD146-PE or anti-STRO-1-
allophycocyanin (APC) for 1 h at room temperature in the dark. As a negative control, 
PE- and APC-conjugated nonspecific mouse IgG1 were substituted for the primary 
antibodies. The cell suspensions were washed twice, re-suspended in 3 % FBS/PBS and 
analysed with a flow cytometry cell sorting Vantage cell sorter (Becton & Dickinson). 
The data were analysed with a Mod-Fit 2.0 cell cycle analysis program (Becton & 
Dickinson). 
Real time quantitative PCR (qPCR) 
Total RNA was extracted from the cells using an RNeasy Mini Kit (QIAGEN) 
according to manufacturer’s directions. The total yield of RNA per extraction was 
calculated using a Nanovue spectrophotometer (GE Healthcare) to measure the 
absorbance at 260 nm. A260/A280 ratios of 1.9 -2.1 indicated extraction of high quality 
RNA. cDNA was synthesised with 2000ng RNA using MMLV reverse transcriptase 
(Promega). For qPCR, three separate cDNA samples were used and each measured in 
triplicate. Target specific primers (Table 1) were added to each cDNA sample together 
with Precision MasterMix with ROX and SYBRgreen (PrimerDesign). The PCR 
reaction was run by ABI Prism fast7500 qPCR system (Advanced Biosystems) under 
the following cycling conditions: an initial denaturation step of 95°C for 2 minutes 
followed by 40 cycles of 15 seconds denaturation (95°C) and 1 minute 
annealing/elongation at 60°C. The relative amount or fold change of the target gene 
expression was normalized relative to the level of D-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and relative to a control sample (non-induced cells). 
Table 1 
Genes Forward and reverse primers Accession number 
GAPDH 5'-GCACCGTCAAGGCTGAGAAC-3' 
5'-TGGTGAAGACGCCAGTGGA-3' 
NM_002046.3 
α-SMA(ACTA2) 5'-CCGGTTGGCCTTGGGGTTCAGGGGTGCC-3' NM_001141945.1 
5'-TCTCTCCAACCGGGGTCCCCCCTCCAGCG-3' 
Myosin(MYH11) 
 
Desmin 
 
Calponin 
 
TGF-β1 
 
HGF 
 
VEGF 
 
PDGF-BB 
 
b-FGF 
 
EGF 
5'-AAGAAAGACACAAGTATCACGGGAGAGC-3' 
5'-TGTCACATTAATTCCCATGAGGTGGCAA-3' 
5'-CACCATGAGCCAGGCCTACTCGTCCA-3' 
5'-GGCAGCCAAATTGTTCTCTGCTTCTTCC-3' 
5'-GGCTCCGTGAAGAAGATCAATGAGTCAA-3' 
5'-CCCTAGGCGGAATTGTAGTAGTTGTGTG-3' 
5'-ATGCCGCCCTCCGGGCTGCGG-3' 
5'-CAGCTGCACTTGCAGGAGCGC-3' 
5'-TACAGGGGCACTGTCAATACC-3' 
5'-GGATACTGAGAATCCCAACGC-3' 
5'-ACGTACTTGCAGATGTGACAAG-3' 
5'-GTGGCGGCCGCTCTA-3' 
5'-ATGAATCGCTGCTGGGCGCTC-3' 
5'-CTAGGCTCCAAGGGTCTCCTTC-3' 
5'-ACGGGGTCCGGGAGAAGAGC-3' 
5'-TGCCCAGTTCGTTTCAGTGCCA-3' 
5'-CTTGTCATGCTGCTCCTCCT-3' 
5'-GAGGGCATATGAAAGCTTCG-3' 
NM_001040113.1 
 
NM_001927.3 
 
NM_001299.4 
 
NM_000660 
 
NM_000601.4 
 
NM_001025366.2 
 
NM_002608.3 
 
NM_002006.4 
 
NM_001963.4 
 
Western blot analysis 
The total protein was extracted from the cells with lysis buffer containing protease 
inhibitors (Roche, UK). The protein concentration was measured by a BCA-200 protein 
assay kit (Pierce, USA). Equal amounts of proteins were separated by 4-12 % sodium 
dodecyl sulfate/polyacrylamide gel electrophoresis and transferred to a polyvinylidene 
fluoride (PVDF) membrane. The membrane was blocked in TRIS-buffered saline with 
Tween (TBST) containing 5 % fat-free milk for 2 h and probed with primary antibodies, 
p-GSK3β (1:1000; Cell signaling), t- GSK3β (1:1000; Cell signaling), active-β-catenin 
(1:1000; Cell signaling), myosin (1:500; Sigma), α-SMA (1:500; Sigma), desmin 
(1:500, Sigma) and GAPDH (1:1000; Cell signaling) overnight at 4 °C and then 
incubated for 2 h with a horseradish-peroxidase-conjugated anti-mouse IgG antibody 
or anti-rabbit IgG diluted 1:20,00 (Cell signaling). Protein bands were visualized on X-
ray film by using an enhance chemiluminescence system (GE Healthcare, 
Buckinghamshire, UK). The relative protein expression intensities were quantified by 
densitometry using Quantity One analysis software. 
Statistical analysis 
Each experiment was performed at least three times, unless otherwise indicated. Data 
are reported as the mean ±SD (standard deviation) deviation from three independent 
experiments. The significance of the differences between the experimental and the 
control groups was determined by using one-way analysis of variance; P<0.05 indicated 
statistical significance. 
 
Results 
The proliferation and differentiation ability of three clones of human dental pulp stem 
cells (DPSCs) (A11, B11 and A32) and characterization of A32 
Dental pulp cells were isolated from pulp tissue of extracted third molars from patients. 
Three clones of cells that adhered to fibronectin were selected, noted as A11, B11 and 
A32, respectively. The proliferation rate and differentiation potential of the three clones 
were analysed. A32 demonstrated a high proliferation capacity extending beyond 
80PDs, whilst the other two clones (A11 and B11) exhibited less than 36PDs (Fig 1A). 
Compared to A11 and B11 clones, A32 showed the best differentiation capacity into 
three mesenchymal lineages including osteogenic, adipogenic and chondrogenic 
competency (Fig 1B. b. f. j). The clone A32 was further characterized by flow 
cytometric analysis, which revealed that A32 was negative for CD34 and CD45. The 
culture population contained 99.8% CD29-positive cells, 100% CD90-positive cells, 
64.4% CD146-positive cells and 27.2% STRO-1-positive cells (Fig 1C). 
The smooth muscle layer-like phenotype generated by DPSCs clone A32 after SMC-
induction. 
Our previous study proved that the DPSC clone A32 displayed the potential to 
differentiate into SMCs by induction of CM from bladder SMCs in combination with 
TGF-β1. In this study, we evaluate whether DPSCs can generate a smooth muscle layer 
after an extended differentiation duration. Noninduced A32 were found to express 𝛼-
SMA (Fig 2A) and desmin (Fig 2I) already, but none of these cells stained positive for 
myosin (Fig 2E). The induced cells from clone A32 formed monolayer structure and 
also generated the smooth muscle-like phenotype which were shown to be positive for 
the SMC markers such as α-SMA (Fig 2B-D), myosin (Fig 2F-H) and desmin (Fig 2J-
L) after a longer period of differentiation (up to 20 days). 
The involvement of Wnt mediated GSK3β/β-catenin in the SMCs-differentiation from 
DPSCs clone A32 
The Wnt-GSK3β/β-catenin signaling pathway has been previously reported to play an 
important role in TGF-β1 induced MSC differentiation. To investigate whether this 
canonical Wnt signaling is also involved in the bladder SMC differentiation from 
DPSCs, we evaluated the protein level of phosphorylation GSK3β (p-GSK3β), total 
GSK3β (t-GSK3β) and active β-catenin in A32 in response to the induction of 
differentiation medium by western blotting. The protein level of p-GSK3β increased 
and maintained at the peak through 11 to 14 days (Fig 3A and B). While, the protein 
level of t-GSK3β did not change (Fig 3A). As for the expression of active β-catenin, a 
significant up-regulation was detected since day 8 of induction, which reached to the 
peak expression at day 11 (Fig 3C and D). 
Inhibition of Wnt-GSK3β/β-catenin signaling pathway prohibits the SMC specific 
markers in DPSCs clone A32 following SMC-induction. 
To further investigate whether canonical Wnt signaling is required for the SMC-
differentiation of cell clone A32, we assessed the SMC specific markers, including α-
SMA, myosin and desmin, in the presence or absence of Wnt/β-catenin specific 
inhibitor, XAV939 and GSK3 inhibitors, SB216763 and LiCl. Pharmacological 
inhibition of Wnt and GSK3 significantly down-regulated the protein expression of p-
GSK3β (Fig 4A and C) and active β-catenin (Fig 4B and D), but had no effect on t-
GSK3β (Fig 4A). The inhibition triggered a further reduction on the expression of SMC 
specific markers including α-SMA, myosin and desmin, at both gene and protein levels 
(Fig 4E-L), compared to those of the non-inhibitor treated control group of A32 
following an SMC-induction protocol for 14 days.  
Growth factor analysis in SMC-differentiation from A32 
The mRNA expression of growth factors, including bFGF, EGF, TGF-β1, HGF, VEGF 
and PDGF-BB in the process of SMC-differentiation from DPSC clone A32 were 
detected by qPCR. The mRNA expression of TGF-β1 was notably increased through 5 
to 14 days of differentiation (Fig 5A); the HGF and VEGF expression both increased 
since day 8 of differentiation, and reached its peak level at day 14 (Fig 5B and C); the 
PDGF-BB expression appeared to go up after 11 day differentiation and reached the 
highest level at day 14 (Fig 5D); the bFGF expression rose to its peak at day 5, but 
subsequently dropped with 14-day induction (Fig 5E)；the EGF expression level was 
increased and maintained through 11 days of differentiation, and then down-regulated 
by day 14 (Fig 5F).  
Wnt-GSK3β/β-catenin signaling pathway promotes DPSCs clone A32 differentiate into 
mature SMC via regulating the expression of growth factors. 
We have demonstrated that Wnt-GSK3β/β-catenin signaling as well as several key 
growth factors were required in the process of human DPSCs differentiating into human 
bladder SMCs. To further confirm the involvement of Wnt signaling in the process of 
SMCs-differentiation from clone A32 by regulating the expression of growth factors, 
pharmacological inhibitors of Wnt pathway were used to evaluate the change of gene 
expression of several key growth factors at the later stage of SMC differentiation. After 
14 days of differentiation, the gene expression of several growth factors including TGF-
β1, HGF, PDGF-BB, HGF and VEGF markedly up-regulated (Fig 6A-D). Whilst either 
Wnt/β-catenin specific inhibitor (XAV939) or GSK-3 inhibitors (SB216763 and LiCl) 
significantly down-regulated the expression levels of these growth factors (Fig 6A-D), 
which suggests a promoting effect of Wnt-mediated GSK-3β/β-catenin signaling on 
SMC-differentiation of clone A32 by regulating the release of growth factors including 
TGF-β1, HGF, PDGF-BB and VEGF. 
 
Discussion 
SMC-based tissue engineering provides a potential therapy for SMC pathology, 
including cardiovascular diseases, gastrointestinal diseases, urinary incontinence and 
bladder dysfunction [29-31]. A reliable cell source of healthy SMCs that can be easily 
obtained and safely expanded plays a vital role in promoting the progress of smooth 
muscle tissue engineering. DPSCs have demonstrated the advantages of easy access 
with the least invasive procedures and little inherent immunogenicity but without any 
ethical issues, which make them a promising cell population for developing tissue 
engineering and regenerative medicine [16]. In order to use DPSCs for clinical therapy, 
in vitro expansion and differentiation ability should be taken into account for the 
success of clinical applications in tissue engineering. In this study, three clones of 
DPSCs from two patients were isolated, which were named as A11, A32 (from patient 
A), and B11 (from patient B). Investigation of the proliferation rate using PDs as an 
indicator demonstrated that two of clones (A11 and B11) showed less than 36PDs and 
senesced within 85 days, while A32 had a high proliferation rate with over 85PDs that 
only started senescing after more than 300 days. Compared with the previous studies 
about the analysis of proliferation rate of MSCs from bone marrow [32-34], stem cell 
clone A32 displayed a better proliferation capacity, giving this clone a potential 
advantage. It has been reported that only a small percentage of the overall clonal 
population of DPSCs, which is less than 5% of the total population, have the ability to 
differentiate into three mesenchymal lineages, including osteoblast, chondrocytes and 
adipocytes [35-37]. Whilst our data demonstrated that all the three clones (A32, A11, 
B11) displayed good ability to differentiate into the osteogenic phenotype, among 
which A32 was able to differentiate into three different lineages. This result is 
consistent with data presented by Halleux et al (2001), in which 24 designated clones 
differentiated into osteogenic lines, while 17/24 and 18/24 clones differentiated into 
chondrogenic and adipogenic lineages, respectively [35]. The niche of these clones 
located and different stages of their development may be accountable for their different 
growth kinetic profiles and differentiation abilities. Therefore, DPSCs clone A32 which 
has the best proliferation and differentiation ability was selected for further bladder 
tissue engineering research. We characterized clone A32 by using flow cytometric 
analysis. The cell populations were positive for a range of mesenchymal stem cells 
markers including CD29, CD90, CD146 and STRO-1, but negative for hematopoietic 
stem cells markers, such as CD34 and CD45, which demonstrated that the clone A32 
are sourced from the mesenchymal stem cells, not hematopoietic stem cells. 
The urinary bladder wall is mainly composed of Detrusor smooth muscle layer which 
is made of smooth muscle fibers arranged in spiral, longitudinal, and circular bundles 
[38]. Detrusor smooth muscle is mainly responsible for storing urine under low pressure 
and contraction for voiding, lined by a layer of transitional cells that provide a barrier 
to absorption. Therefore, it is a crucial step to regenerate Detrusor smooth muscle layer 
as a tissue specific effort for the tissue engineering of the urinary bladder. Previous 
study in our lab has demonstrated that 𝛼-SMA and desmin were already present in 
noninduced human DPSCs clone A32 at a low basal level, which indicates A32 may be 
more suitable to be induced into SMCs for bladder tissue regeneration. Additionally, 
this clone has the potential to differentiate into bladder SMC by the CM from cultured 
bladder SMC in combination with TGF-β1 [20]. In this study, we further proved that 
A32 could generate a smooth muscle layer-like phenotype after an extended 
differentiation duration. Further functional analysis would be required using 3D cell 
culture by seeding the DPSCs-derived smooth muscle layer-like structure into synthetic 
bladder composites and transplanting them into nude rats which underwent removal of 
half bladder, in order to evaluate its regeneration capacity of the Detrusor smooth cells 
in vivo. 
Canonical Wnt/β-catenin signaling plays a primary role in the regulation of 
proliferation and differentiation of stem cells [21, 39]. GSK3 exists as two highly 
homologous isoforms encoded by distinct genes known as GSK3α and GSK3β.  
GSK3β originally isolated from muscles as a kinase promotes glycogen assimilation by 
phosphorylating and inactivating glycogen synthase. It is also involved in the 
maintenance and plasticity of skeletal muscle mass, as well as plays an important role 
in skeletal muscle atrophy in vivo [40, 41]. β-catenin is a multifunctional protein which 
is located in both the nucleus and cytoplasm. It leads to myogenic specification and 
prevents adipogenic differentiation in adult stem cells [42-44]. GSK3β and β-catenin 
are key factors in the canonical Wnt pathway. Activation of the Wnt signaling promotes 
the stabilization and accumulation of β-catenin in the cytoplasm by triggering GSK3β 
phosphorylation which prevents subsequent GSK3β mediated β-catenin 
phosphorylationin association with axin and adenomatous polyplsis coli (APC) [21]. 
The stabilized β-catenin enters the nucleus and induces activation of target genes by 
binding with members of the T-cell factor (TCF) and lymphoid enhancer factor (LEF) 
transcription factor family [45]. It has been reported that Wnt-GSK3β/β-catenin 
contribute to the progressive nature of smooth muscle tissue remodelling [22] and also 
acts as an indispensable regulator for myogenesis in embryogenesis and postnatal 
muscle regeneration [46], as well as induces myogenic differentiation in stem cells 
during muscle regeneration [42]. In this study, we found that Wnt-GSK3β/β-catenin 
signaling is involved in regulating the process of bladder SMC differentiation from 
human DPSCs by the SMC induction protocol. To confirm the effect of Wnt/β-catenin 
signaling and GSK3β on the SMCs differentiation, two types of pharmacological 
inhibitors were used. One is XAV939 which is a Tankyrase inhibitor for inhibiting 
Wnt/β-catenin signaling [28]. The others are SB216763 and LiCl which block GSK3 
activation [26, 27]. SB-216763 is a small molecule that competes with ATP and 
potently inhibits the activity α and β isozymes of GSK3. Considering the high degree 
of sequence similarity, GSK3α and GSK3β share some similar functions. For example, 
the single loss of either GSK3α or GSK3β in mouse embryonic stem cells (ESC) did 
not negatively alter Wnt/β-catenin signaling, whereas GSK3α/β double knockout ESCs 
displayed hyperactivated Wnt/β-catenin signaling, resulting in dramatically skewed cell 
differentiation [47]. Nevertheless, the two isoforms were shown to have opposite effects 
on the transcriptional activation of certain transcription factors [48]. GSK3α or GSK3β 
play distinct roles in cardiomyocyte differentiation and cardiovascular development in 
mice [49-51]. Therefore, it appears that GSK3α and GSK3β have both common and 
non-overlapping cellular functions, largely depending on the physiological context and 
the cell type studied. It has been reported GSK3β protein expression in human and 
mouse muscle was found to be three to four times higher than GSK3α, suggesting that 
GSK3β, rather than GSK3α may be the predominant GSK3 isoform in muscle [6]. Two 
types of inhibitors significantly suppressed the activation of p-GSK3β as well as active 
β-catenin, and also down-regulated the expression of SMCs markers (especially myosin 
which is only expressed in contractile SMCs) at the later stage of differentiation at both 
mRNA and protein levels. It suggests that Wnt-GSK3β/β-catenin signaling promotes 
the human DPSCs differentiate into bladder SMCs. Further analysis would be required 
by down-regulation of GSK3α or GSK3β to investigate the role of GSK3α in regulating 
the process of DPSCs differentiation into SMC. 
Previous studies have identified that a variety of stem cells, including those from 
embryo [52, 53], bone morrow [54], adipose tissue [55] and dental pulp tissue [20] can 
be induced to differentiate into bladder SMCs by using differentiation agents, such as 
CM from SMC culture in addition to myogenic growth factors, or by indirectly co-
culturing with the target cells. The CM or indirect co-culture system contain cytokine 
growth factors secreted by the target cells that can be used to induce cell differentiation 
[56]. Here, we showed that several growth factors, including TGF-β1, HGF, VEGF, 
PDGF-BB, bFGF and EGF play different roles in the process of SMC differentiation. 
It has been demonstrated that TGF-β1 evokes an important signal that induces 
expression of vascular SMC markers in a range of non-smooth muscle precursor cell 
types, including multipotent embryonic fibroblast [57], neural crest cells [58], and 
MSCs [54]. We here found that the expression of TGF-β1 up-regulated during the 
whole process of SMC differentiation, indicating that TGF-β1 also play an important 
role in the bladder SMC differentiation from DPSCs. It has been shown previously that 
an increased expression of bFGF was associated consistently with SMC proliferation 
of the neointima formation [59] and atheromatous lesions [60] in vivo. Additionally, 
experimental inhibition of bFGF activation leads to the SMC markers expression in the 
model of BMMSC differentiation into SMC [8]. As one of the most important 
mitogenic growth factors, bFGF is known to promote proliferation of marrow cells [61], 
which is consistent with our data. Because the phenomenon of DPSC proliferation was 
observed when the expression of bFGF was up-regulated during 5 days of SMC-
differentiation (data not shown). PDGF-BB, which is previously associated with 
proliferation and differentiation of SMCs [62, 63], was up-regulated after 11 days 
differentiation in our study, indicating that this growth factor is mainly for promoting 
bladder SMC differentiation from DPSCs. As for the expression of myogenic growth 
factors, such as HGF and VEGF, they were both up-regulated after 8 days 
differentiation, which is consistent with the previous study of BMMSC differentiation 
into bladder SMCs [54]. The expression levels of the growth factors, including TGF-
β1, HGF, VEGF and PDGF-BB, were all up-regulated at 14 days differentiation, 
indicating that these growth factors may induce the mature of SMCs at the later stage 
of bladder SMC differentiation from DPSCs. In order to further investigate whether 
Wnt-GSK3β/β-catenin signaling is involved in the mature process of SMC 
differentiation, we evaluated the expression of growth factors above with or without 
two types of inhibitors at a late stage of SMC differentiation. We noticed that the 
expression of these growth factors was significantly down-regulated with the Wnt/β-
catenin inhibitor and GSK3β inhibitors at that stage, indicating that the Wnt-GSK3β/β-
catenin signaling promotes the human DPSCs differentiate into mature bladder SMCs 
by regulating the expression of these myogenic growth factors.  
As summarized in Figure 7, we hypothesize that the canonical Wnt which is activated 
by CM from SMCs in combination with TGF-β1 triggers phosphorylation of GSK3β, 
thus disrupts the APC/Axin/GSK3β/β-catenin complex. The stabilization and 
accumulation of β-catenin in cytoplasm translocates into the nucleus and enhances the 
expression of growth factors, including TGF-β1, HGF, VEGF and PDGF-BB, which 
subsequently promote the SMC differentiation from DPSCs, for instance, clone A32.   
Conclusion 
In this study we characterized one of our DPSCs clones (clone A32) with the best 
proliferation and differentiation abilities, and demonstrated that the clone A32 
possesses a potential to differentiate into bladder smooth muscle cell layer-like 
phenotype in vitro using the bladder SMCs induction protocol we established before. 
Additionally, we have found that the Wnt-GSK3β/β-catenin signaling is involved in the 
SMC differentiation. Several growth factors (including TGF-β1, HGF, VEGF, PDGF-
BB and bFGF) regulated by Wnt-GSK3β/β-catenin signaling promote the 
proliferation/differentiation during the process of bladder SMC differentiation from 
human DPSCs.  
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Fig. 1 The ability of proliferation and differentiation analysis for three clones of human 
dental pulp stem cells (DPSCs) (A11, B11 and A32) and characterization of A32 
Population doublings (PDs) of three clones (A11, B11 and A32) from different patients 
(A). The differentiating potential of the three clones into osteogenic (alizarin red 
staining) (B. b-d), adipogenic (oil-red-o staining) (B. f-h) and chondrogenic lineages 
(safranin o staining) (B. j-l) when cultured in differentiation condition compared to 
control groups, respectively (B. a, c, i). A32 had the potential to differentiate into 
osteogenic (B. b), adipogenic (B. f), and chondrogenic lineages (B. j). A11 and B11 
had the potential to differentiate into osteogenic lineages (B. c and d). Analysis of 
molecular surface antigen markers in A32 by flow cytometry (P2 positive zone of 
antigen) indicated that A32 were negative for CD34 and CD45, whereas they were 
positive for CD29 and CD90; of cells 64.4% were CD146-positive and 27.2% STRO-
1-positive (C). PE- and APC- conjugated non-specific mouse IgG1 served as negative 
controls. 
 
 
Fig. 2 The smooth muscle layer-like phenotype generated by dental pulp stem cells 
(DPSCs) clone A32 after SMC-induction. 
After a long period of differentiation (20 days), the induced A32 formed monolayer and 
generated the smooth muscle-like phenotype which were positive for expression of the 
SMC markers, α-SMA (B-D), myosin (F-H) and desmin (J-L). Noninduced A32 as the 
negative control (A, E, I). The green staining indicates a positive result. Nuclei were 
stained with DAPI. Bars 50 μm. 
 
Fig.3 The involvement of Wnt mediated GSK3β/β-catenin in SMCs-differentiation 
from DPSCs clone A32. The A32 clone was induced according to the SMCs induction 
protocol, 20% conditioned medium and 2.5ng/mL TGF-β1 for the indicated time (0d, 
5d, 8d, 11d and 14d). The protein levels of p-GSK3β, t-GSK3β and β-catenin were 
analysed with western blotting (A and C). The relative band intensities were determined 
by dentitometry (B and D). Statistical analysis was performed by using one-way 
ANOVA. Date are shown as means ± SEM. *P<0.05 when compared with the 0d group. 
 
 Fig. 4 Inhibition of Wnt-GSK3β/β-catenin prohibits the SMC-differentiation from 
DPSCs clone A32. The A32 clone was induced following the SMCs induction protocol 
with or without Wnt/β-catenin specific pharmacological inhibitor, XAV939, as well as 
the GSK3 inhibitors, SB216763 and LiCl for 14d. The mRNA expression of α-SMA, 
myosin, desmin and calponin were analysed with qPCR (E-H); the protein levels of p-
GSK3β, t-GSK3β, active β-catenin, α-SMA, myosin, and desmin were analysed with 
western blotting (A, B and I). The relative band intensities were determined by 
dentitometry (C, D and J-L). Statistical analysis was performed by using one-way 
ANOVA. Date are shown as means ± SEM. *P<0.05 when compared with the control 
group. 
 
 Fig. 5 Growth factor analysis in SMC-differentiation from DPSCs clone A32. The A32 
clone was induced following the SMCs induction protocol for the indicated time (0d, 
5d, 8d, 11d and 14d). The mRNA expression of TGF-β1 (A), HGF (B), VEGF (C), 
PDGF-BB (D), bFGF (E) and EGF (F) were analysed with qPCR. Statistical analysis 
was performed by using one-way ANOVA. Date are shown as means ± SEM. *P<0.05 
when compared with the 0D group. 
 Fig. 6 Wnt/GSK3β/β-catenin is involved in the process of SMC-differentiation from 
DPSCs clone A32 through regulating on growth factors.  
The A32 clone was induced following the SMCs induction protocol with or without the 
Wnt/β-catenin specific inhibitor, XAV939, as well as GSK3 inhibitors, SB216763 and 
LiCl for 14d. The mRNA expression of TGF-β1 (A), HGF (B), PDGF-BB (C) and 
VEGF (D) were analysed with qPCR. Statistical analysis was performed by using one-
way ANOVA. Data are shown as means ± SEM. *P<0.05 when compared with the 
control group. 
 Fig. 7 Wnt/GSK3β/β-catenin activation. 1. In the absence of canonical Wnt signaling, 
β-catenin is complexed with GSK3β, APC and Axin, which facilitate the 
phosphorylation and subsequent degradation of β-catenin. 2. Activation of canonical 
Wnt signaling by the growth factor, TGF-β1 and CM from SMCs triggers 
phosphorylation of GSK3β, thereby disrupting the APC/Axin/GSK3β/β-catenin 
complex. 3. β-catenin which dissociates from the APC–Axin–GSK3β complex escapes 
from degradation and accumulates in the cytoplasm. 4. The stabilization and 
accumulation of β-catenin translocates into the nucleus and enhances the expression of 
growth factors, including TGF-β1, HGF, VEGF, PDGF-BB, thus promoting the SMCs 
differentiation from DPSCs clone A32. 5. Wnt/β-catenin signaling inhibitor, XAV939 
and GSK3 inhibitor, SB216763 and LiCl were used to block the Wnt/GSK3β/β-catenin 
signaling. 
 
 
 
 
 
 
Reference 
1. K. I. Glassberg, "Current issues regarding posterior urethral valves," Urol Clin North Am, 
vol. 12, no. 1, pp. 175-185, 1985. 
2. D. A. Kiddoo, M. C. Carr, S. Dulczak and D. A. Canning, "Initial management of complex 
urological disorders: bladder exstrophy," Urol Clin North Am, vol. 31, no. 3, pp. 417-426, vii-
viii, 2004. 
3. W. T. Snodgrass and R. Adams, "Initial urologic management of myelomeningocele," Urol 
Clin North Am, vol. 31, no. 3, pp. 427-434, viii, 2004. 
4. W. S. McDougal, "Metabolic complications of urinary intestinal diversion," J Urol, vol. 147, 
no. 5, pp. 1199-1208, 1992. 
5. T. M. Soergel, M. P. Cain, R. Misseri, T. A. Gardner, M. O. Koch and R. C. Rink, 
"Transitional cell carcinoma of the bladder following augmentation cystoplasty for the 
neuropathic bladder," J Urol, vol. 172, no. 4 Pt 2, pp. 1649-1651; discussion 1651-1642, 2004. 
6. J. Y. Lai, C. Y. Yoon, J. J. Yoo, T. Wulf and A. Atala, "Phenotypic and functional 
characterization of in vivo tissue engineered smooth muscle from normal and pathological 
bladders," J Urol, vol. 168, no. 4 Pt 2, pp. 1853-1857; discussion 1858, 2002. 
7. C. Danielsson, S. Ruault, A. Basset-Dardare and P. Frey, "Modified collagen fleece, a 
scaffold for transplantation of human bladder smooth muscle cells," Biomaterials, vol. 27, no. 
7, pp. 1054-1060, 2006. 
8. A. Kanematsu, S. Yamamoto, E. Iwai-Kanai, I. Kanatani, M. Imamura, R. M. Adam, Y. 
Tabata and O. Ogawa, "Induction of smooth muscle cell-like phenotype in marrow-derived 
cells among regenerating urinary bladder smooth muscle cells," Am J Pathol, vol. 166, no. 2, 
pp. 565-573, 2005. 
9. Z. Gong, G. Calkins, E. C. Cheng, D. Krause and L. E. Niklason, "Influence of culture 
medium on smooth muscle cell differentiation from human bone marrow-derived mesenchymal 
stem cells," Tissue Eng Part A, vol. 15, no. 2, pp. 319-330, 2009. 
10. A. I. Caplan, "Mesenchymal stem cells," J Orthop Res, vol. 9, no. 5, pp. 641-650, 1991. 
11. M. F. Pittenger, A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. 
Moorman, D. W. Simonetti, S. Craig and D. R. Marshak, "Multilineage potential of adult 
human mesenchymal stem cells," Science, vol. 284, no. 5411, pp. 143-147, 1999. 
12. B. M. Strem, K. C. Hicok, M. Zhu, I. Wulur, Z. Alfonso, R. E. Schreiber, J. K. Fraser and 
M. H. Hedrick, "Multipotential differentiation of adipose tissue-derived stem cells," Keio J 
Med, vol. 54, no. 3, pp. 132-141, 2005. 
13. W. A. Robinson, J. E. Kurnick and B. L. Pike, "Colony growth of human leukemic 
peripheral blood cells in vitro," Blood, vol. 38, no. 4, pp. 500-508, 1971. 
14. K. Bieback, S. Kern, H. Kluter and H. Eichler, "Critical parameters for the isolation of 
mesenchymal stem cells from umbilical cord blood," Stem Cells, vol. 22, no. 4, pp. 625-634, 
2004. 
15. S. Gronthos, M. Mankani, J. Brahim, P. G. Robey and S. Shi, "Postnatal human dental pulp 
stem cells (DPSCs) in vitro and in vivo," Proc Natl Acad Sci U S A, vol. 97, no. 25, pp. 13625-
13630, 2000. 
16. W. J. Longxing Ni, "Tissue Engineering and Regenerative Medicine, From and Beyond the 
Dentistry," Dentistry, vol. 05, no. 06, 2015. 
17. H. O. Trowbridge, "Pulp biology: progress during the past 25 years," Aust Endod J, vol. 29, 
no. 1, pp. 5-12, 2003. 
18. A. Karystinou, F. Dell'Accio, T. B. Kurth, H. Wackerhage, I. M. Khan, C. W. Archer, E. 
A. Jones, T. A. Mitsiadis and C. De Bari, "Distinct mesenchymal progenitor cell subsets in the 
adult human synovium," Rheumatology (Oxford), vol. 48, no. 9, pp. 1057-1064, 2009. 
19. R. J. Waddington, S. J. Youde, C. P. Lee and A. J. Sloan, "Isolation of distinct progenitor 
stem cell populations from dental pulp," Cells Tissues Organs, vol. 189, no. 1-4, pp. 268-274, 
2009. 
20. B. Song, W. Jiang, A. Alraies, Q. Liu, V. Gudla, J. Oni, X. Wei, A. Sloan, L. Ni and M. 
Agarwal, "Bladder Smooth Muscle Cells Differentiation from Dental Pulp Stem Cells: Future 
Potential for Bladder Tissue Engineering," Stem Cells International, vol. 2016, pp. 1-11, 2016. 
21. J. L. Teo and M. Kahn, "The Wnt signaling pathway in cellular proliferation and 
differentiation: A tale of two coactivators," Adv Drug Deliv Rev, vol. 62, no. 12, pp. 1149-1155, 
2010. 
22. R. Gosens, H. Meurs and M. Schmidt, "The GSK-3/beta-catenin-signalling axis in smooth 
muscle and its relationship with remodelling," Naunyn Schmiedebergs Arch Pharmacol, vol. 
378, no. 2, pp. 185-191, 2008. 
23. Y. Shang, C. Zhang, S. Wang, F. Xiong, C. Zhao, F. Peng, S. Feng, M. Yu, M. Li and Y. 
Zhang, "Activated beta-catenin induces myogenesis and inhibits adipogenesis in BM-derived 
mesenchymal stromal cells," Cytotherapy, vol. 9, no. 7, pp. 667-681, 2007. 
24. Y. Zhang, H. K. Lin, D. Frimberger, R. B. Epstein and B. P. Kropp, "Growth of bone 
marrow stromal cells on small intestinal submucosa: an alternative cell source for tissue 
engineered bladder," BJU Int, vol. 96, no. 7, pp. 1120-1125, 2005. 
25. W. Jiang, H. Lv, H. Wang, D. Wang, S. Sun, Q. Jia, P. Wang, B. Song and L. Ni, "Activation 
of the NLRP3/caspase-1 inflammasome in human dental pulp tissue and human dental pulp 
fibroblasts," Cell Tissue Res, vol. 361, no. 2, pp. 541-555, 2015. 
26. S. Guo, K. Arai, M. F. Stins, D. M. Chuang and E. H. Lo, "Lithium upregulates vascular 
endothelial growth factor in brain endothelial cells and astrocytes," Stroke, vol. 40, no. 2, pp. 
652-655, 2009. 
27. J. Liu, B. Zhu, G. Zhang, J. Wang, W. Tian, G. Ju, X. Wei and B. Song, "Electric signals 
regulate directional migration of ventral midbrain derived dopaminergic neural progenitor cells 
via Wnt/GSK3beta signaling," Exp Neurol, vol. 263, pp. 113-121, 2015. 
28. S. M. Huang, Y. M. Mishina, S. Liu, A. Cheung, F. Stegmeier, G. A. Michaud, O. Charlat, 
E. Wiellette, Y. Zhang, S. Wiessner, M. Hild, X. Shi, C. J. Wilson, C. Mickanin, V. Myer, A. 
Fazal, R. Tomlinson, F. Serluca, W. Shao, H. Cheng, M. Shultz, C. Rau, M. Schirle, J. Schlegl, 
S. Ghidelli, S. Fawell, C. Lu, D. Curtis, M. W. Kirschner, C. Lengauer, P. M. Finan, J. A. 
Tallarico, T. Bouwmeester, J. A. Porter, A. Bauer and F. Cong, "Tankyrase inhibition stabilizes 
axin and antagonizes Wnt signalling," Nature, vol. 461, no. 7264, pp. 614-620, 2009. 
29. Z. Gong and L. E. Niklason, "Small-diameter human vessel wall engineered from bone 
marrow-derived mesenchymal stem cells (hMSCs)," FASEB J, vol. 22, no. 6, pp. 1635-1648, 
2008. 
30. C. R. Chapple, N. I. Osman, A. Mangera, C. Hillary, S. Roman, A. Bullock and S. Macneil, 
"Application of Tissue Engineering to Pelvic Organ Prolapse and Stress Urinary Incontinence," 
Low Urin Tract Symptoms, vol. 7, no. 2, pp. 63-70, 2015. 
31. A. Atala, S. B. Bauer, S. Soker, J. J. Yoo and A. B. Retik, "Tissue-engineered autologous 
bladders for patients needing cystoplasty," Lancet, vol. 367, no. 9518, pp. 1241-1246, 2006. 
32. G. T. Huang, S. Gronthos and S. Shi, "Mesenchymal stem cells derived from dental tissues 
vs. those from other sources: their biology and role in regenerative medicine," J Dent Res, vol. 
88, no. 9, pp. 792-806, 2009. 
33. Y. Tamaki, T. Nakahara, H. Ishikawa and S. Sato, "In vitro analysis of mesenchymal stem 
cells derived from human teeth and bone marrow," Odontology, vol. 101, no. 2, pp. 121-132, 
2013. 
34. D. L. Alge, D. Zhou, L. L. Adams, B. K. Wyss, M. D. Shadday, E. J. Woods, T. M. Gabriel 
Chu and W. S. Goebel, "Donor-matched comparison of dental pulp stem cells and bone 
marrow-derived mesenchymal stem cells in a rat model," J Tissue Eng Regen Med, vol. 4, no. 
1, pp. 73-81, 2010. 
35. C. Halleux, V. Sottile, J. A. Gasser and K. Seuwen, "Multi-lineage potential of human 
mesenchymal stem cells following clonal expansion," J Musculoskelet Neuronal Interact, vol. 
2, no. 1, pp. 71-76, 2001. 
36. T. Okamoto, T. Aoyama, T. Nakayama, T. Nakamata, T. Hosaka, K. Nishijo, T. Nakamura, 
T. Kiyono and J. Toguchida, "Clonal heterogeneity in differentiation potential of immortalized 
human mesenchymal stem cells," Biochem Biophys Res Commun, vol. 295, no. 2, pp. 354-361, 
2002. 
37. K. C. Russell, D. G. Phinney, M. R. Lacey, B. L. Barrilleaux, K. E. Meyertholen and K. C. 
O'Connor, "In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage 
potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment," Stem 
Cells, vol. 28, no. 4, pp. 788-798, 2010. 
38. Y. de Jong, J. H. Pinckaers, R. M. ten Brinck, A. A. Lycklama a Nijeholt and O. M. Dekkers, 
"Urinating standing versus sitting: position is of influence in men with prostate enlargement. A 
systematic review and meta-analysis," PLoS One, vol. 9, no. 7, pp. e101320, 2014. 
39. L. Ling, V. Nurcombe and S. M. Cool, "Wnt signaling controls the fate of mesenchymal 
stem cells," Gene, vol. 433, no. 1-2, pp. 1-7, 2009. 
40. N. Embi, D. B. Rylatt and P. Cohen, "Glycogen synthase kinase-3 from rabbit skeletal 
muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase," Eur 
J Biochem, vol. 107, no. 2, pp. 519-527, 1980. 
41. J. R. Woodgett and P. Cohen, "Multisite phosphorylation of glycogen synthase. Molecular 
basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen 
synthase kinase-5)," Biochim Biophys Acta, vol. 788, no. 3, pp. 339-347, 1984. 
42. A. Polesskaya, P. Seale and M. A. Rudnicki, "Wnt signaling induces the myogenic 
specification of resident CD45+ adult stem cells during muscle regeneration," Cell, vol. 113, 
no. 7, pp. 841-852, 2003. 
43. J. De Boer, H. J. Wang and C. Van Blitterswijk, "Effects of Wnt signaling on proliferation 
and differentiation of human mesenchymal stem cells," Tissue Eng, vol. 10, no. 3-4, pp. 393-
401, 2004. 
44. F. Belema Bedada, A. Technau, H. Ebelt, M. Schulze and T. Braun, "Activation of 
myogenic differentiation pathways in adult bone marrow-derived stem cells," Mol Cell Biol, 
vol. 25, no. 21, pp. 9509-9519, 2005. 
45. L. Li, H. Yuan, W. Xie, J. Mao, A. M. Caruso, A. McMahon, D. J. Sussman and D. Wu, 
"Dishevelled proteins lead to two signaling pathways. Regulation of LEF-1 and c-Jun N-
terminal kinase in mammalian cells," J Biol Chem, vol. 274, no. 1, pp. 129-134, 1999. 
46. M. Ikeya and S. Takada, "Wnt signaling from the dorsal neural tube is required for the 
formation of the medial dermomyotome," Development, vol. 125, no. 24, pp. 4969-4976, 1998. 
47. B. W. Doble, S. Patel, G. A. Wood, L. K. Kockeritz and J. R. Woodgett, "Functional 
redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an 
allelic series of embryonic stem cell lines," Dev Cell, vol. 12, no. 6, pp. 957-971, 2007. 
48. M. H. Liang and D. M. Chuang, "Differential roles of glycogen synthase kinase-3 isoforms 
in the regulation of transcriptional activation," J Biol Chem, vol. 281, no. 41, pp. 30479-30484, 
2006. 
49. T. Force and J. R. Woodgett, "Unique and overlapping functions of GSK-3 isoforms in cell 
differentiation and proliferation and cardiovascular development," J Biol Chem, vol. 284, no. 
15, pp. 9643-9647, 2009. 
50. R. Kerkela, L. Kockeritz, K. Macaulay, J. Zhou, B. W. Doble, C. Beahm, S. Greytak, K. 
Woulfe, C. M. Trivedi, J. R. Woodgett, J. A. Epstein, T. Force and G. S. Huggins, "Deletion of 
GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast 
hyperproliferation," J Clin Invest, vol. 118, no. 11, pp. 3609-3618, 2008. 
51. J. Cho, P. Rameshwar and J. Sadoshima, "Distinct roles of glycogen synthase kinase (GSK)-
3alpha and GSK-3beta in mediating cardiomyocyte differentiation in murine bone marrow-
derived mesenchymal stem cells," J Biol Chem, vol. 284, no. 52, pp. 36647-36658, 2009. 
52. H. Huang, X. Zhao, L. Chen, C. Xu, X. Yao, Y. Lu, L. Dai and M. Zhang, "Differentiation 
of human embryonic stem cells into smooth muscle cells in adherent monolayer culture," 
Biochem Biophys Res Commun, vol. 351, no. 2, pp. 321-327, 2006. 
53. A. L. Firth and J. X. Yuan, "Human models for smooth muscle cell differentiation. Focus 
on "A novel in vitro model system for smooth muscle differentiation from human embryonic 
stem cell-derived mesenchymal cells"," Am J Physiol Cell Physiol, vol. 304, no. 4, pp. C287-
288, 2013. 
54. H. Tian, S. Bharadwaj, Y. Liu, P. X. Ma, A. Atala and Y. Zhang, "Differentiation of human 
bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue 
engineering," Tissue Eng Part A, vol. 16, no. 5, pp. 1769-1779, 2010. 
55. L. V. Rodriguez, Z. Alfonso, R. Zhang, J. Leung, B. Wu and L. J. Ignarro, "Clonogenic 
multipotent stem cells in human adipose tissue differentiate into functional smooth muscle 
cells," Proc Natl Acad Sci U S A, vol. 103, no. 32, pp. 12167-12172, 2006. 
56. S. Fukuhara, S. Tomita, S. Yamashiro, T. Morisaki, C. Yutani, S. Kitamura and T. Nakatani, 
"Direct cell-cell interaction of cardiomyocytes is key for bone marrow stromal cells to go into 
cardiac lineage in vitro," J Thorac Cardiovasc Surg, vol. 125, no. 6, pp. 1470-1480, 2003. 
57. K. K. Hirschi, S. A. Rohovsky and P. A. D'Amore, "PDGF, TGF-beta, and heterotypic cell-
cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their 
differentiation to a smooth muscle fate," J Cell Biol, vol. 141, no. 3, pp. 805-814, 1998. 
58. N. M. Shah, A. K. Groves and D. J. Anderson, "Alternative neural crest cell fates are 
instructively promoted by TGFbeta superfamily members," Cell, vol. 85, no. 3, pp. 331-343, 
1996. 
59. V. Lindner and M. A. Reidy, "Proliferation of smooth muscle cells after vascular injury is 
inhibited by an antibody against basic fibroblast growth factor," Proc Natl Acad Sci U S A, vol. 
88, no. 9, pp. 3739-3743, 1991. 
60. S. E. Hughes, D. Crossman and P. A. Hall, "Expression of basic and acidic fibroblast growth 
factors and their receptor in normal and atherosclerotic human arteries," Cardiovasc Res, vol. 
27, no. 7, pp. 1214-1219, 1993. 
61. D. Orlic, J. Kajstura, S. Chimenti, F. Limana, I. Jakoniuk, F. Quaini, B. Nadal-Ginard, D. 
M. Bodine, A. Leri and P. Anversa, "Mobilized bone marrow cells repair the infarcted heart, 
improving function and survival," Proc Natl Acad Sci U S A, vol. 98, no. 18, pp. 10344-10349, 
2001. 
62. J. Yamashita, H. Itoh, M. Hirashima, M. Ogawa, S. Nishikawa, T. Yurugi, M. Naito and K. 
Nakao, "Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors," 
Nature, vol. 408, no. 6808, pp. 92-96, 2000. 
63. M. Stehr, R. M. Adam, J. Khoury, L. Zhuang, K. R. Solomon, C. A. Peters and M. R. 
Freeman, "Platelet derived growth factor-BB is a potent mitogen for rat ureteral and human 
bladder smooth muscle cells: dependence on lipid rafts for cell signaling," J Urol, vol. 169, no. 
3, pp. 1165-1170, 2003. 
 
